日本における経口血糖降下薬で治療された2型糖尿病患者の臨床的特徴と診療パターン：MDV医療・健康データベースの分析

基本情報

NCT ID

NCT03092752

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

162,116

治験依頼者名

Boehringer Ingelheim

概要

Appropriate use of oral antidiabetic drugs (OADs) including dose-reduction is important for patient's safety in T2DM patients with renal impairment (RI). However, there are insufficient data on dose adjustment in accordance with the prescription pattern and the risk of RI of OADs, in particular Dipeptidyl-peptidase-4 inhibitors, in clinical practice in Japan. Therefore, we will investigate OADs usage conditions and dose selection in T2DM patients with RI in clinical practice in Japan

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)